Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07ZFH
|
|||
| Former ID |
DNC013929
|
|||
| Drug Name |
FGGFTRKRKSARKLANQ
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C86H145N31O22
|
|||
| Canonical SMILES |
CC(C)CC(C(=O)NC(C)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(CCCN=C(N)N)NC(=O)C(C(C)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)C(CC2=CC=CC=C2)N
|
|||
| InChI |
1S/C86H145N31O22/c1-46(2)39-60(78(133)104-48(4)70(125)114-62(42-65(92)121)79(134)113-59(83(138)139)31-32-64(91)120)115-76(131)54(26-13-16-34-88)109-73(128)56(28-18-36-99-84(93)94)107-69(124)47(3)105-81(136)63(45-118)116-77(132)55(27-14-17-35-89)110-74(129)57(29-19-37-100-85(95)96)111-72(127)53(25-12-15-33-87)108-75(130)58(30-20-38-101-86(97)98)112-82(137)68(49(5)119)117-80(135)61(41-51-23-10-7-11-24-51)106-67(123)44-102-66(122)43-103-71(126)52(90)40-50-21-8-6-9-22-50/h6-11,21-24,46-49,52-63,68,118-119H,12-20,25-45,87-90H2,1-5H3,(H2,91,120)(H2,92,121)(H,102,122)(H,103,126)(H,104,133)(H,105,136)(H,106,123)(H,107,124)(H,108,130)(H,109,128)(H,110,129)(H,111,127)(H,112,137)(H,113,134)(H,114,125)(H,115,131)(H,116,132)(H,117,135)(H,138,139)(H4,93,94,99)(H4,95,96,100)(H4,97,98,101)/t47-,48-,49+,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,68-/m0/s1
|
|||
| InChIKey |
SNTZLYOXEWYFBE-UTPVZXCMSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nociceptin receptor (OPRL1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.